Introduction
Currently used therapeutic approaches such as regular blood transfusions and iron chelation have prolonged the life expectancy of patients with thalassemia, but this brings new complications. There have been numerous reports of thromboembolic complications associated with thalassemia, recently. Venous thromboembolic events such as deep venous thrombosis, portal venous thrombosis, pulmonary embolism, postsplenectomy thrombosis, and cerebral thromboembolism have been observed in thalassemic patients. l-4 At the end of the 1980s, a study concerning survival and causes of death in thalassemia major (TM) patients showed that thromboembolism represented Thalassemia major patients have increased risk for thromboembolic complications because of the chronic hypercoagulable state. The question arising from this is whether thromboembolic complications are the result of genetic polymorphisms of prothrombotic factors. Here, we studied factor V 1691 G-A (FVL), factor II polymorphism (G20210A), methyltetrahydrofolate reductase mutation (MTHFR, C677T), and endothelial cell protein C receptor (EPCR) deletion polymorphism and their relationship with thromboembolic complications. We found significant decrements of protein C and protein S and a slight increased prevalence of congenital thrombophilic mutations when compared with controls. Although 5 of the patients had high soluble EPCR (sEPCR) levels, no significant change was found in sEPCR values between patients and controls.
Patients and Methods

Patients
Forty-eight patients with TM (25 female and 23 male;  age 2-29 years, median 16 years; 15/48 splenectomized) were enrolled in the study. The diagnosis of TM was carried out within the first year of life on the basis of anemia, hemoglobin electrophoresis, and detection of the thalassemia trait in both parents. Patients received regular blood transfusions and subcutaneous desferrioxamine infusion at doses in keeping with the severity of iron overload. All splenectomized patients had been operated on at least 6 months before the study. Control samples were obtained from healthy volunteers.
Informed written consent was obtained from all the patients and/or their parents. Hematological parameters were studied before transfusion. Blood was drawn under aseptic conditions for all the tests. Complete blood count, routine biochemical parameters, serum ferritin, protein C and protein S free antigen, AT activity, factor VIII levels, factor IX levels, and soluble endothelial cell protein C receptor (sEPCR) levels were studied, and protein C < 70%, protein S < 70%, and AT III < 80% were taken as low values. A prothrombin (PT) value 2 seconds more than that in controls and an activated partial thromboplastin time (aPTT) value 6 seconds more than that in controls were taken as abnormal. Factor V 1691 G-A (FVL), factor II 20210 G-A, and methyltetrahydrofolate reductase 677 C-T (MTHFR) mutations were identified by melting curve analysis using the real time PCR method on Light Cycler (Roche Diagnostics, Germany). EPCR polymorphisms were performed according to a previously described method. 12 Soluble EPCR levels were determined in plasma using sEPCR Asserachrom enzyme-linked immunosorbent assay (ELISA) kits from Diagnostica Stago (Asnières, France), according to the manufacturer's instructions. Samples were assayed in duplicate. Measurements of plasma sEPCR levels of the patient group were performed after 6 months from the first episode of stroke. Plasma levels of 31 to 138 ng/mL were accepted as normal in our laboratory.
Results
Fifteen patients had undergone splenectomy. All the patients had hepatomegaly, with mild to moderate impairment seen in liver function tests. None of the patients had any thromboembolic or bleeding manifestations. The hematological parameters are given in Table 1 . Protein C, protein S, and AT III values were low in 29.4%, 38.2%, and 2.9% of patients, respectively. Elevated factor VIII levels were found in 2 (8.3%) thalassemia patients. Elevated factor IX levels were not seen in any of the patients.
The prevalence of heterozygosity was 17% (8/48) and homozygosity was 2% (1/48) for the FVL mutation; 2% of patients (1/48) were heterozygous for the PT 20210A mutation, and none were homozygous. The MTHFR genotype was 40% for CC, 52% for CT, and 8% for TT in patients ( Table 2 ). Frequencies of the T allele for patients and controls were 0.3437 and 0.2642, respectively; the difference was insignificant.
The distribution of the 23 bp insertion of exon III of the EPCR gene was studied in 43 patients. We could not find this mutation in any of our patients. Seven patients (16.3%) had elevated sEPCR levels, and the incidence of elevated sEPCR levels in patients and controls was 16.3% and 24.6%, respectively. There was no significant difference between patients and controls. (P = .34; Table 3 ).
Discussion
Although patients with TM are apparently liable to thromboembolic complications because of their hypercoagulable state, we did not see any thromboembolic or bleeding manifestations in our group either in the clinical history or on examination. The phospholipid structure of the red-blood-cell (RBC) membrane was damaged, and the procoagulant phosphatidyl-serine was translocated in the outer surface of the RBC membrane. 1, 13, 14 The membrane changes may explain the enhanced aggregation of RBCs and their capacity to enhance thrombin generation. At the end, platelets and endothelial cells were activated and tissue factor released. All these factors enhance the thrombotic process. The low levels of the anticoagulant factors such as protein C, protein S, and AT III contribute to this hypercoagulable condition. 1, 11 Naithani et al 10 found that the prolongation of PT time was 40.7%, and prolongation of aPTT was 46.3%. In our study group, it was found to be 6.3% for PT and 14.6% for aPTT. Bleeding complications such as epistaxis, gum bleeds, and cutaneous bleeds were seen in 29.6% of patients in their group. But the percentage prolongation of PT and aPTT in our study group was low, so this finding explains why none of our patients had any bleeding manifestations. Naithani et al 10 reported that protein C was low in 26.2% of patients, protein S was low in 28.6%, and AT III was low in 46.8% of cases. In our study group, protein C, protein S, and AT III values were found to be low in 29.4%, 38.2%, and 2.9% of our patients respectively. Eldor et al 15 found significantly decreased protein C and protein S levels in all TM patients, and AT III levels were normal. Singer et al 16 reported that protein C and protein S levels were below normal in the majority of their thalassemia patients.
The possibility of a genetic basis for the hypercoagulable state in thalassemia patients is not clear. Eldor et al 15 found no increased prevalence of congenital thrombophilic mutations, including the FVL, PT G20210A, and MTHFR C677T mutations. Finkelstein et al 17 found 5 patients (5/23) had specific mutations indicating hereditary thrombophilia in their TM patients group. Furthermore, 3 different studies revealed controversial data, of which one was from Lebanon in β-thalassemia intermedia patients with high FVL mutation and one from Turkey after splenectomy. 4, 18, 19 The frequencies of FVL 1691 G-A and PT 20210 G-A mutations are 10.4% and 2.7%, respectively, in the Turkish population. [20] [21] [22] When compared with previously reported data, there is a marked increase in frequency for our β-thalassemia patients. In the literature, there are some reports on EPCR polymorphisms and sEPCR in patients with thrombosis. 23, 24 But we could not find any report on the effect of EPCR polymorphisms and sEPCR on the pathogenesis of thrombosis in thalassemic patients. In our patients, we could not find the EPCR insertion polymorphism. However, 5 patients (11.6%) had elevated sEPCR levels. These patients may have the A3 haplotype of the EPCR gene, which needs further analysis.
In conclusion, we found significantly decreased protein C and protein S in our TM patients and a slightly increased prevalence of congenital thrombophilic mutations. Even if thromboembolic complications could be explained by the hypercoagulable state found in TM patients, following the first thrombotic event, such as deep venous thrombosis, portal venous thrombosis, pulmonary embolism, strokes, peripheral arterial and venous thromboses, pulmonary hypertension, or development of cor-pulmonale, they should be investigated for congenital thrombophilia. When they are exposed to thrombotic risk factors such as immobilization, surgery, and delivery, prophylactic antithrombotic agents may be recommended. 
